Company’s 36-month beta value is 1.85.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 1 as “sell.”
The public float for CDNA is 50.22M, and currently, short sellers hold a 7.90% ratio of that floaft. The average trading volume of CDNA on January 15, 2025 was 813.91K shares.
CDNA) stock’s latest price update
The stock price of Caredx Inc (NASDAQ: CDNA) has dropped by -12.05 compared to previous close of 25.07. Despite this, the company has seen a fall of -5.53% in its stock price over the last five trading days. zacks.com reported 2025-01-14 that CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CDNA’s Market Performance
CDNA’s stock has fallen by -5.53% in the past week, with a monthly drop of -8.81% and a quarterly drop of -27.99%. The volatility ratio for the week is 10.23% while the volatility levels for the last 30 days are 6.50% for Caredx Inc The simple moving average for the past 20 days is -0.13% for CDNA’s stock, with a 7.41% simple moving average for the past 200 days.
Analysts’ Opinion of CDNA
Many brokerage firms have already submitted their reports for CDNA stocks, with Wells Fargo repeating the rating for CDNA by listing it as a “Underweight.” The predicted price for CDNA in the upcoming period, according to Wells Fargo is $28 based on the research report published on August 28, 2024 of the previous year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see CDNA reach a price target of $40. The rating they have provided for CDNA stocks is “Buy” according to the report published on August 19th, 2024.
CDNA Trading at -3.99% from the 50-Day Moving Average
After a stumble in the market that brought CDNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.71% of loss for the given period.
Volatility was left at 6.50%, however, over the last 30 days, the volatility rate increased by 10.23%, as shares sank -6.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.05% lower at present.
During the last 5 trading sessions, CDNA fell by -5.53%, which changed the moving average for the period of 200-days by +109.60% in comparison to the 20-day moving average, which settled at $22.08. In addition, Caredx Inc saw 2.99% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDNA starting from Novack Jeffrey Adam, who sale 1,917 shares at the price of $26.00 back on Dec 04 ’24. After this action, Novack Jeffrey Adam now owns 110,237 shares of Caredx Inc, valued at $49,842 using the latest closing price.
Jeffrey Adam Novack, the Officer of Caredx Inc, proposed sale 1,917 shares at $24.96 during a trade that took place back on Dec 04 ’24, which means that Jeffrey Adam Novack is holding shares at $47,848 based on the most recent closing price.
Stock Fundamentals for CDNA
Current profitability levels for the company are sitting at:
- -0.18 for the present operating margin
- 0.65 for the gross margin
The net margin for Caredx Inc stands at -0.46. The total capital return value is set at -0.15. Equity return is now at value -43.02, with -29.35 for asset returns.
Based on Caredx Inc (CDNA), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at 0.26.
Currently, EBITDA for the company is -89.66 million with net debt to EBITDA at 1.64. When we switch over and look at the enterprise to sales, we see a ratio of 3.57. The receivables turnover for the company is 4.69for trailing twelve months and the total asset turnover is 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.10.
Conclusion
In a nutshell, Caredx Inc (CDNA) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
